Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 90

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 90
---
) a relocation bonus of $250,000; and (vii) severance benefits as further described below. The stock options, RSUs and PSUs were granted outside our 2013 Stock Incentive Plan, as an inducement material to Mr. Goff’s entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). In connection with her appointment as chief financial officer, we entered into an employment agreement with Ms. Jones, effective September 26, 2022, providing for the terms of her employment, including (i) an annual base salary of $475,000; (ii) an annual target bonus of at least 45% of her base salary, to be pro-ratedwith respect to 2022; (iii) a one-time grant ofan option to purchase 118,390 shares of common stock at an exercise price of $27.88 per share, the closing price on the date of grant, which vested as to 25% of the underlying shares on September 26, 2023 and vests as to the remaining shares on a monthly basis thereafter; (iv) a one-time grantof 22,417 RSUs, each unit representing a contingent right to receive one share of common stock, which vest in equal annual installments on the first, second and third anniversaries of the date of grant; (v) a one-time grantof 68

10,760 PSUs, each unit representing a contingent right to receive one share of common stock, which vested as to one-halfof the underlying shares of common stock upon the achievement of specified clinical and regulatory milestones, which are more fully described under “2022 PSU Program” above; (vi) a sign-onbonus of $175,000; and (vii) severance benefits as further described below. The stock options, RSUs and PSUs were granted outside our 2013 Stock Incentive Plan, as an inducement material to Ms. Jones’ entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). In connection with her appointment as chief commercial officer, we entered into an employment agreement with Ms. Milanova, effective December 5, 2022, providing for the terms of her employment, including (i) an annual base salary of $510,000; (ii) an annual target bonus of at least 45% of her base salary; (iii) a one-time grant ofan option to